Form 4: PACB COO Sells Shares for Tax Obligations

Pacific Biosciences' Chief Operating Officer, Mark Van Oene, sold 26,836 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Mark Van Oene, Chief Operating Officer of Pacific Biosciences of California, Inc. (PACB), sold 26,836 shares of common stock.
• The transaction occurred on August 18, 2025, at a weighted average sale price of $1.311 per share, with prices ranging from $1.30 to $1.32.
• The sale was an automatic transaction executed to cover tax withholding obligations in connection with the vesting of restricted stock units.
• Following this reported transaction, Mark Van Oene beneficially owns 1,920,035 shares of common stock.

Sentiment

Score: 5

Explanation: The transaction is an administrative sale to cover tax obligations from RSU vesting, which is a neutral event and not indicative of discretionary selling or a change in company fundamentals.

Positives

• The underlying event, the vesting of restricted stock units, represents a form of executive compensation and retention.

Negatives

• The sale of shares by an insider, even for tax purposes, reduces their direct equity stake in the company.

Risks

• No specific risks are detailed in this administrative filing beyond the general implications of insider transactions.

Future Outlook

This filing, a Form 4, does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sale represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

Industry Context

This administrative filing reports an individual insider transaction and does not provide broader industry context or trends.

Comparison to Industry Standards

• This type of transaction, an automatic sale of shares to cover tax obligations upon RSU vesting, is a standard practice for executive compensation across various industries and is not indicative of company-specific performance issues.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in the executive's direct equity stake, but it is an administrative action related to compensation rather than a discretionary divestment.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• No specific future actions, events, or milestones are mentioned in this administrative filing.

Key Dates

Recommendation

The reported transaction is an automatic sale of shares by an executive to cover tax withholding obligations related to the vesting of restricted stock units. This is a routine administrative event and does not reflect a discretionary decision by the executive to reduce their stake, thus it does not provide a basis for a change in investment recommendation.

Keywords

PACB, Pacific Biosciences, insider trading, Form 4, stock sale, executive compensation, Mark Van Oene, restricted stock units, RSU